Alex Shimmings
Executive Editor, Europe Commercial
Latest From Alex Shimmings
What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet
Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19 has abated, finds a new report from Citeline.
What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet
Industry-sponsored clinical trial activity has returned to pre-pandemic trends now that the turmoil of COVID-19 has abated, finds a new report from Citeline.
Orphan Drugs – Slowdown Signals New Paths Ahead
Signs are that the rate of sales growth for orphan drugs is slowing but that does not mean that they have had their day. Far from it, finds a new report from Evaluate.
Orphan Drugs – Slowdown Signals New Paths Ahead
Signs are that the rate of sales growth for orphan drugs is slowing but that does not mean that they have had their day. Far from it, finds a new report from Evaluate.
The Shifting Sands Of Biopharma R&D
A year is a long time in biopharma. Pharmaprojects’ annual pipeline review finds changes in the therapeutic spread of drug candidates and a reordering of the top R&D companies, as Chinese firms made their presence felt all the more over the past 12 months.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.